Panel Discussion: The Cell and Gene Therapy Outlook – What is the Current State of Play in KSA? (CME Credits)

The goal is to make C> more affordable and accessible. Saudi and other countries have excellent facilities but are very dependent on importation at a center costs, time and flexibility. We want to innovate in the development of those cutting- edge products. In the area of mRNA this is also an opportunity at the point of care. Saudi could be a leader and not a follower in this area.